Adding Retifanlimab To Chemotherapy Provides OS Benefit over Chemotherapy In First-Line Treatment of Patients with Advanced Squamous Anal Cancer By Ogkologos - May 18, 2026 193 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the final overall survival analysis in the POD1UM-303/InterAACT-2 study Source RELATED ARTICLESMORE FROM AUTHOR ESMO contributes to discussions on the future of cancer care at EU Cancer Mission event Multicancer early detection test detects tumour-derived cfDNA and demonstrates robust performance characteristics with a favourable safety profile Anito-cel, a d-Domain BCMA CAR T-Cell, Induces Rapid, Deep, and Durable Responses in Patients with Heavily Pretreated Relapsed or Refractory Multiple Myeloma MOST POPULAR The future of research: meet three of our scientists working on... December 13, 2022 27-Year-Old Fighting Stage IV Cancer Gets Hit By COVID-19 And Sepsis... May 29, 2020 From smart knives to virtual reality tumours: five innovations in understanding... August 29, 2022 Initial Results of the CanScreen5, an Authentic Data Repository for Cancer... May 4, 2023 Load more HOT NEWS Finding Purpose in Sharing Your Story: A Q&A With Esophageal Cancer... Scientists developing urine and blood tests to detect brain tumours FDA Approves Allogeneic Regulatory T Cell-Based Immunotherapy with HSPC and T... ESMO Breast Cancer 2025, Munich, Germany, 14-17 May 2025
